Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

GlobeNewswire

December 25, 2022



- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the...

Related Keywords

Guangzhou ,Guangdong ,China ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,Chinese ,Sheng Yao ,Junshi Bioscience ,Marek Ciszewski ,Jodi Sievers ,Junshi Biosciences ,Theresa Lavallee ,Coherus Biosciences ,Zhi Li ,Development Officer ,Exchange Commission On ,Ir Team ,Coherus Biosciences Inc ,Drug Administration ,Nasdaq ,Exchange Commission ,Vp Corporate Communications ,Pr Team ,Shanghai Junshi Biosciences Co Ltd ,Coherus Share Update ,Biologics License Application ,Metastatic Nasopharyngeal Carcinoma ,Prescription Drug User Fee Action ,Senior Vice President ,Both Coherus ,Coheru Chief Development ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Chinese Academy ,Emergency Use Authorizations ,Private Securities Litigation Reform Act ,Coheru Annual Report ,